19
3
Cat. No. | Product Name | Target | Signaling Pathways |
---|---|---|---|
T2601 |
Vidofludimus
SC12267,4sc-101 |
Dehydrogenase; DNA/RNA Synthesis; Interleukin | Cell Cycle/Checkpoint; DNA Damage/DNA Repair; Immunology/Inflammation; Metabolism |
Vidofludimus (SC12267) 是一种新型的二氢乳清酸脱氢酶 (DHODH) 小分子抑制剂,可在不影响淋巴细胞增殖的条件下抑制IL-17的分泌。 | |||
T2233 |
GW 4064
|
FXR; Autophagy | Autophagy; Metabolism |
GW 4064 是一种有效的法尼醇 X 受体 (FXR) 激动剂,EC50为 65 nM。 | |||
T7886 |
Nidufexor
|
FXR; Autophagy | Autophagy; Metabolism |
Nidufexor 是一种可口服的法尼醇 X 受体激动剂,可研究非酒精性脂肪性肝炎。 | |||
T8471 |
Vonafexor
EYP001,PLX007,pxl007 |
FXR; HBV | Metabolism; Microbiology/Virology |
Vonafexor (EYP001) 是一种法尼醇 X 受体激动剂,具有抗 HBV 作用。 | |||
T2015 |
Fexaramine
|
FXR; Autophagy | Autophagy; Metabolism |
Fexaramine 是小分子法尼醇 X 受体 (FXR) 激动剂,EC50为 25 nM,与天然化合物相比,亲和力提高了 100 倍。 | |||
T11428 |
Glyco-Obeticholic acid
|
FXR | Metabolism |
Glyco-obeticholic acid 是一种牛磺酸的特性代谢物。Obeticholic Acid 是口服具有活性的法尼样 X 受体激动剂。 | |||
T1789 |
Obeticholic Acid
奥贝胆酸,INT-747,6-Ethylchenodeoxycholic acid,6-ECDCA |
FXR; Autophagy | Autophagy; Metabolism |
Obeticholic Acid (6-ECDCA) 是一种选择性的,有口服活性的 FXR 激动剂,EC50为 99 nM。它可诱导细胞自噬,具有抗胆碱和抗炎作用。 | |||
T11426 |
Gly-β-MCA
|
FXR | Metabolism |
Gly-β-MCA 是一种具有口服生物活性、肠道选择性和有效的法尼酯X受体 (FXR) 抑制剂,是一种胆汁酸,可用于研究肥胖和糖尿病。 | |||
T7436 |
Cilofexor
|
FXR; Autophagy | Autophagy; Metabolism |
Cilofexor 是一种法尼醇 X 受体激动剂,EC50为 43 nM。它抑制合成肽的结合,具有抗炎和抗纤维化作用。它可用于原发性硬化性胆管炎和非酒精性脂肪性肝炎的研究。 | |||
T8818 |
TC-G 1005
(4-环丙基-3,4-二氢-1(2H)-喹喔啉基)[4-(2,5-二甲基苯氧基)-3-吡啶基]甲酮 |
GPCR19 | GPCR/G Protein |
TC-G 1005 是具有口服活性的TGR5选择性激动剂,能够激活 hTGR5 (EC50:0.72 nM)和 mTGR5 (EC50:6.2 nM)。它能够减少小鼠体内葡萄糖水平。 | |||
T13093 |
Tauro-β-muricholic acid sodium
T-βMCA sodium |
FXR | Metabolism |
Tauro-β-muricholic Acid sodium is a endogenous metabolite, is a competitive and reversible antagonist of farnesoid X receptor (FXR)(IC50 of 40 μM). | |||
T27492 |
GSK-8062
GSK 8062 |
||
GSK-8062 is an agonist of farnesoid X receptor (FXR). | |||
T69724 | Cilofexor tromethamine | ||
Cilofexor, also known as GS-9674, is a farnesoid X receptor (FXR) agonist. The nonsteroidal FXR agonist cilofexor (GS-9674) improves markers of cholestasis and liver injury in patients with PSC. In clinical study, cilofexor was well tolerated and led to significant improvements in liver biochemistries and markers of cholestasis in patients with PSC. | |||
T11661 |
INT-767
|
FXR; GPCR19 | GPCR/G Protein; Metabolism |
INT-767 是一种高效的法尼类固醇 X 受体 (FXR)/TGR5 双激动剂,可预防 NASH 并促进内脏脂肪棕色脂肪生成和线粒体功能,可用于研究非酒精性脂肪性肝炎。 | |||
T37416 |
Tauro-α-muricholic Acid (sodium salt)
|
||
Tauro-α-muricholic acid (TαMCA) is an antagonist of the farnesoid X receptor (FXR; IC50 = 28 μM) and a taurine-conjugated form of the murine-specific primary bile acid α-muricholic acid . TαMCA is common in rodents but has also been found in small amounts in human serum. | |||
T37414 |
CAY10771
|
||
CAY10771 is a dual agonist of farnesoid X receptor (FXR) and peroxisome proliferator-activated receptor δ (PPARδ).1It activates FXR and PPARδ in reporter assays using HEK293T cells (EC50s = 0.94 and 1.5 μM, respectively) and is selective for these receptors over retinoic acid receptor α (RARα), retinoid X receptor α (RXRα), PPARα, PPARγ, and liver X receptor α (LXRα) at 10 μM. 1.Schierle, S., Neumann, S., Heitel, P., et al.Design and structural optimization of dual FXR/PPARδ activatorsJ. Med. Ch... | |||
T73414 | EDP-305 | ||
EDP-305是一种具有选择性的口服farnesoid X受体(FXR)激动剂,其EC50值分别为34 nM(CHO细胞嵌合性FXR)和8 nM(HEK细胞全长FXR)。该化合物展现了强大且持久的抗纤维化效果,并适用于原发性胆道胆管炎(PBC)与非酒精性脂肪性肝炎(NASH)的研究。 | |||
T83858 |
Tauro-Obeticholic Acid sodium
Tauro-6-Ethylchenodeoxycholic Acid,Tauro-6-Ethyl-CDCA,Obeticholic Acid Taurine Conjugate,Tauro-OCA,T-ECDCA |
||
陶氏奥贝胆酸是奥贝胆酸的活性代谢物,属于法尼索德X受体(FXR)激动剂并且是熊脱氧胆酸的半合成衍生物。陶氏奥贝胆酸通过在肝脏中与牛磺酸结合形成,但可以通过肠道微生物被再次转换回奥贝胆酸。 | |||
T70899 |
Vidofludimus hemicalcium
4sc-101 hemicalcium,SC12267 hemicalcium,4sc-101 hemicalcium ; SC12267 hemicalcium |
||
Vidofludimus (4sc-101 ; SC12267) hemicalcium 是一种口服有效的二氢乳清酸脱氢酶 (DHODH) 的抑制剂,也是法尼醇 X 受体 (FXR) 调节剂。Vidofludimus hemicalcium 作为一种免疫调节剂,可用于研究自身免疫性疾病,如炎症性肠病 (IBD)。Vidofludimus hemicalcium 还可通过靶向FXR 用于脂肪肝的研究。 |
Cat. No. | Product Name | Target | Signaling Pathways |
---|---|---|---|
T13092 |
Tauro-Obeticholic acid
|
FXR | Metabolism |
Tauro-Obeticholic acid 是一种牛磺酸的特性代谢物。Obeticholic Acid 是口服具有活性的法尼样 X 受体激动剂。 | |||
T75538 | Alismanol M | ||
Alismanol M,一种法尼酯 X 受体 (FXR) 激动剂,具有 50.25 μM 的 EC50 值。作为一种源自东方红根茎的原丹类三萜化合物,Alismanol M 主要应用于胆汁淤积与非酒精性脂肪性肝炎的研究。 | |||
T36563 |
(E)-Guggulsterone
|
||
Bile acids are essential for solubilization and transport of dietary lipids, are the major products of cholesterol catabolism, and are physiological ligands for farnesoid X receptor (FXR), a nuclear receptor that regulates genes involved in lipid metabolism.1They are also inherently cytotoxic, as physiological imbalance contributes to increased oxidative stress.2,3Bile acid-controlled signaling pathways are promising novel targets to treat such metabolic diseases as obesity, type II diabetes, hy... |